Table 2.
Compound | Structure | BLI concentration to restore IMI (μg/mL) | Fold differentialb | |
---|---|---|---|---|
MB6477 efflux-wta | MB6476 efflux-dela | |||
DABCO #1 | > 100 | 12.5 | > 8-fold | |
DABCO #2 | 50 | 3.125 | 16-fold | |
DABCO #3 | 12.5 | 6.25 | 2-fold | |
Relebactam | 6.25 | 3.125 | 2-fold |
BLI β-lactamase inhibitor, DABCO diazabicyclooctane, IMI imipenem
aMB6477 nfxC, wild-type for other efflux pumps, spontaneous OprD deletion; MB6476 nfxC, Δ [MexAB-OprM] Δ [MexCD-OprJ] Δ [MexXY] Δ [MexJKL] Δ [MexHI-OpmD] Δ [OpmH])
bDifferential between the concentrations required to restore susceptibility to imipenem at 4 μg/mL, expressed as the BLI concentration against MB6477 divided by the BLI concentration against MB6476